Archive for July, 2006
Murex Pharmaceuticals Licenses Ariadne’s Pathway Studio Software Solution To Be Utilized For Cancer Therapeutics Development
Ariadne Genomics, Inc. today announced that Murex Pharmaceuticals (Dallas, Texas) has licensed its Pathway Studio® software solution for the visualization and analysis of biological pathways and gene regulation networks. Murex will use Pathway Studio to develop computer-based models for the identification and validation of cancer targets. (PRWEB Jul 27, 2006)
Trackback URI: http://www.prweb.com/zingpr.php/WmV0YS1NYWduLVpldGEtSGFsZi1JbnNlLVplcm8=
DNA and EDNA Means No Two Alike
The July issue of Paint Horse Journal featured the cutting-edge EDNA test as a solution for recovery of lost or stolen Horses. The Industry Watch section of this affluent subscriber-magazine called EDNA, ?A cutting-edge test that may provide more than just an equine DNA fingerprint.? (PRWEB Jul 18, 2006)
Trackback URI: http://www.prweb.com/zingpr.php/UGlnZy1DcmFzLVN1bW0tU3F1YS1JbnNlLVplcm8=
Leading DNA Forensics Laboratory Receives Full Texas DPS Accreditation
Chromosomal Laboratories begins rapid expansion into Texas forensics market. (PRWEB Jul 15, 2006)
European Union is Not Actually Opposed to Genetic Engineering
The article argues that contrary to popular opinion, the European Union is not opposed to genetic modification. (PRWEB Jul 15, 2006)
Ryogen Licenses Human Aminopeptidase P Gene Patent to R&D SYSTEMS
Ryogen LLC (Ryogen) headquartered in Suffern, NY and R&D Systems, Inc. (RDSI) of Minneapolis, MN, a wholly owned subsidiary of TECHNE Corporation (NASDAQ: TECH), announced today that they have entered into a nonexclusive license agreement whereby RDSI has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene. (PRWEB Jul 8, 2006)